Last reviewed · How we verify
MK-4280A
MK-4280A is a selective antagonist of the chemokine receptor CCR4 that reduces the recruitment and activation of regulatory T cells and other immune cells to the tumor microenvironment.
MK-4280A is a selective antagonist of the chemokine receptor CCR4 that reduces the recruitment and activation of regulatory T cells and other immune cells to the tumor microenvironment. Used for Advanced or metastatic solid tumors (in combination with checkpoint inhibitors).
At a glance
| Generic name | MK-4280A |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | CCR4 antagonist |
| Target | CCR4 (C-C chemokine receptor type 4) |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
CCR4 is highly expressed on regulatory T cells (Tregs) and certain effector T cell populations. By blocking CCR4, MK-4280A prevents these cells from migrating to tumor sites via CCL17 and CCL22 chemokine gradients, thereby reducing immunosuppression in the tumor microenvironment and enhancing anti-tumor immune responses. This mechanism aims to restore anti-tumor immunity and improve checkpoint inhibitor efficacy.
Approved indications
- Advanced or metastatic solid tumors (in combination with checkpoint inhibitors)
Common side effects
- Infusion-related reactions
- Immune-mediated adverse events
- Fatigue
- Diarrhea
Key clinical trials
- Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) (PHASE2)
- Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98) (PHASE1, PHASE2)
- Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) (PHASE3)
- Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008) (PHASE2)
- Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A) (PHASE1, PHASE2)
- A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008) (PHASE2)
- A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A) (PHASE1, PHASE2)
- A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MK-4280A CI brief — competitive landscape report
- MK-4280A updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI